BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//RESIST - ECPv6.5.1.5//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.resist-cluster.de/en/
X-WR-CALDESC:Events for RESIST
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Berlin
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20260329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20261025T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/Berlin:20260423T130000
DTEND;TZID=Europe/Berlin:20260423T140000
DTSTAMP:20260407T231627
CREATED:20260327T081942Z
LAST-MODIFIED:20260327T082654Z
UID:40290-1776949200-1776952800@www.resist-cluster.de
SUMMARY:RESIST Seminar lecture by Prof. Dr. Britta Eiz-Vesper
DESCRIPTION:Exciting topics\, interestingly presented: Every first and third Thursday (except during school holidays)\, RESIST scientists or top-class researchers from external institutions present their topics at the RESIST seminar series. \nAttend these exciting seminars of the Cluster of Excellence RESIST\, as a member of RESIST or as a colleague or student. \nOn 23 April 2026 at 1:00 p.m.\, Prof. Dr. Britta Eiz-Vesper\, Institute of Transfusion Medicine and Transplant Engineering (ITT)\, will give a lecture on “Personalized adoptive T-cell therapy to treat viral complication”. \nBritta Eiz-Vesper’s research advances allogeneic antiviral T-cell therapy and next-generation CAR/TCR engineering for the treatment of viral infections\, virus-induced malignancies\, solid tumors\, and transplant rejection. She co-founded the world’s first T-cell donor registry (alloCELL.org) and has been instrumental in establishing immune monitoring and quality standards for antiviral T-cell therapies. Her work focuses on identifying suitable T-cell donors\, delivering personalized antiviral immunotherapies to patients in need\, and developing monitoring programs for pathogen-specific T cells in immunocompromised individuals with or without transplants. To date\, more than 800 mono- and multivirus-specific T-cell products have been manufactured for patients at Hannover Medical School (MHH)\, in Germany\, and across Europe. Her current research aims to elucidate the mechanisms that govern the function of adoptively transferred T cells and to further optimize T-cell–based immunotherapies. \nThe lecture will take place in Lecture Hall S\, Building J01 of the Hannover Medical School. \nIf you are interested in participating online\, please contact RESIST@mh-hannover.de. \nDo you have any questions or suggestions about the RESIST seminar series? Then please contact us.
URL:https://www.resist-cluster.de/en/veranstaltung/resist-seminar-guest-lecture-by-dr-lennart-riemann-2-2-2-3/
LOCATION:Hannover Medical School\, Building J6\, Lecture Hall S\, Carl-Neuberg-Str. 1\, Hannover\, 30625
CATEGORIES:seminar (upcoming)
ATTACH;FMTTYPE=image/png:https://www.resist-cluster.de/wp-content/uploads/2026/03/Seminarankuendigung-Eiz-Vesper.png
ORGANIZER;CN="RESIST Cluster of Excellence":MAILTO:RESIST@mh-hannover.de
END:VEVENT
END:VCALENDAR